BEDMINSTER, N.J. & RESEARCH TRIANGLE PARK, N.C. -- (BUSINESS WIRE) -- Aerie Pharmaceuticals, Inc., announced today that Gerald D. Cagle, Ph.D., has been elected to the Company’s Board of Directors, effective immediately. Dr. Cagle brings more than three decades of experience in ophthalmological product development, including as Senior Vice President of R&D and Chief Scientific Officer at Alcon Laboratories, Inc. With the election of Dr. Cagle to Aerie’s Board, the Company’s directors number nine.
“During his career at Alcon, Jerry directed the release of numerous ophthalmology products, spanning the range of therapeutic offerings, including anti-infective, inflammation, allergy, dry eye, and glaucoma products,” stated Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of Aerie Pharmaceuticals. “Jerry’s extensive experience and his relationships within the industry and knowledge of the FDA regulatory process will prove invaluable to Aerie as we continue to advance our novel glaucoma product portfolio, including dual-action AR-13324 and triple-action PG324.”
Dr. Cagle is currently Chief Operating Officer at Cognoptix, Inc., focused on the diagnosis of Alzheimer's disease. He also is Senior Advisor and Head of Business Development for GrayBug, LLC, a platform drug delivery company. Previously, Dr. Cagle served as Senior Vice President of Research & Development at Alcon Laboratories Inc. from 1997 to 2008, assuming the responsibility of Chief Scientific Officer in 2006. Dr. Cagle began his 32-year career at Alcon in 1976 as a Senior Scientist in Microbiology, rapidly advancing to lead the Product Development organization and being named Vice President, Product Development, in 1985. He also served a two-year assignment as the Vice President of Regulatory Affairs. Under Dr. Cagle's leadership, Alcon's Research & Development group grew to 1,300 employees in 18 countries. Dr. Cagle has served on the Wilmer Eye Institute Advisory Council and is a member of the ARVO Foundation Board of Governors. Dr. Cagle received his B.S. degree from Wayland College in Plainview, Texas, and earned both his M.S. and Ph.D. degrees from the University of North Texas in Denton, Texas.
About Aerie Pharmaceuticals
Aerie Pharmaceuticals is a privately held pharmaceutical company in late Phase 2 dedicated to the discovery and development of novel small-molecule treatments for glaucoma. Aerie’s internal research and development engine has generated an innovative glaucoma pipeline of proprietary product candidates, which are well tolerated, high efficacy, once-daily eye drop therapies that include the first new mechanisms of action for glaucoma treatment in nearly 20 years.
The Company’s lead product candidate, AR-13324, is the first of a new dual action drug class that reduces the eye’s fluid inflow while also increasing fluid outflow through the trabecular meshwork, which is the eye’s main fluid drain, all in a highly effective single drop per day. Aerie’s PG324 fixed combination of AR-13324 with latanoprost is a first-in-class glaucoma therapy to lower intraocular pressure by reducing fluid inflow while also opening both of the eye’s fluid drains. This product candidate offers the convenience of two drugs in one eye drop.
Aerie is located in Bedminster, New Jersey and Research Triangle Park, North Carolina. Further information on the Company is available at www.aeriepharma.com.